Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

[1]  W. Borkowsky,et al.  Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2012, The Journal of infectious diseases.

[2]  R. Heyderman,et al.  Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. , 2011, The Journal of infectious diseases.

[3]  T. Puthanakit,et al.  The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. , 2011, Vaccine.

[4]  S. Madhi,et al.  Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. , 2011, Vaccine.

[5]  Cheryl Cohen,et al.  The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis , 2011, AIDS.

[6]  S. Madhi,et al.  Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. , 2010, The Journal of infectious diseases.

[7]  M. Molyneux,et al.  A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. , 2010, The New England journal of medicine.

[8]  W. Borkowsky,et al.  Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2009, The Journal of infectious diseases.

[9]  S. Pelton,et al.  Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. , 2009, The Journal of infectious diseases.

[10]  S. Madhi,et al.  Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. , 2009, The Journal of infectious diseases.

[11]  D. Kelly,et al.  The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response1 , 2008, The Journal of Immunology.

[12]  K. O'Brien,et al.  Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? , 2007, The Lancet. Infectious diseases.

[13]  L. D'Orsogna,et al.  Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy , 2007, AIDS.

[14]  M. Farley,et al.  Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  B. Gazzard,et al.  Loss of Discrete Memory B Cell Subsets Is Associated with Impaired Immunization Responses in HIV-1 Infection and May Be a Risk Factor for Invasive Pneumococcal Disease1 , 2007, The Journal of Immunology.

[16]  Stephanie A. Jones,et al.  Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. , 2007, Vaccine.

[17]  W. Borkowsky,et al.  Immunogenicity, Safety, and Predictors of Response After a Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine Series in Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy , 2006, The Pediatric infectious disease journal.

[18]  L. Lopalco,et al.  Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. , 2006, Blood.

[19]  W. Schaffner,et al.  Changes in Invasive Pneumococcal Disease among HIV-Infected Adults Living in the Era of Childhood Pneumococcal Immunization , 2006, Annals of Internal Medicine.

[20]  M. Theodoridou,et al.  Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. , 2005, Vaccine.

[21]  S. Madhi,et al.  Quantitative and Qualitative Antibody Response to Pneumococcal Conjugate Vaccine Among African Human Immunodeficiency Virus-Infected and Uninfected Children , 2005, The Pediatric infectious disease journal.

[22]  P. Rojo,et al.  Assessment of Antibody Response Elicited by a 7-valent Pneumococcal Conjugate Vaccine in Pediatric Human Immunodeficiency Virus Infection , 2005, Clinical Diagnostic Laboratory Immunology.

[23]  M. Theodoridou,et al.  Haemophilus influenzae type b conjugate vaccine‐induced immunological memory in symptomatic HIV‐1‐infected children , 2003, AIDS.

[24]  J. McVernon,et al.  Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure , 2003, Archives of disease in childhood.

[25]  C. Whitney,et al.  Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. , 2001, Vaccine.

[26]  R. Dagan,et al.  Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. , 2001, The Journal of infectious diseases.

[27]  J. Eskola,et al.  Contribution of serotype‐specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae , 1999, Clinical and experimental immunology.

[28]  A. Lucas,et al.  Avidity as a Determinant of the Protective Efficacy of Human Antibodies to Pneumococcal Capsular Polysaccharides , 1999, Infection and Immunity.

[29]  A. Cnaan,et al.  Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine. , 1996, Archives of pediatrics & adolescent medicine.

[30]  Fifty-sixth Report.  WHO Expert Committee on Biological Standardization. , 2013, World Health Organization technical report series.

[31]  K. O'Brien,et al.  The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. , 2008, The Lancet. Infectious diseases.

[32]  G. Merenstein.  University of Colorado School of Medicine. , 2000, Academic medicine : journal of the Association of American Medical Colleges.